Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ANTEPAR vs CARISOPRODOL
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.
Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.
Treatment of ascariasis (roundworm infection),Treatment of enterobiasis (pinworm infection)
Adjunct to rest, physical therapy, and other measures for the relief of discomfort associated with acute, painful musculoskeletal conditions
Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.
250-350 mg orally 3 times daily and at bedtime
Terminal elimination half-life is approximately 3-4 hours in patients with normal renal function; may be prolonged in renal impairment.
Terminal elimination half-life is approximately 2.0 hours for carisoprodol; the active metabolite meprobamate has a half-life of 6-12 hours. Clinical context: Short half-life supports three-times-daily dosing; accumulation of meprobamate with repeated dosing or renal impairment may prolong effects.
Partially metabolized in the liver; some metabolites are excreted unchanged.
Primarily hepatic via CYP2C19; partially metabolized to meprobamate (a Schedule IV controlled substance) by N-dealkylation; also undergoes hydrolysis and subsequent conjugation.
Renal elimination of unchanged drug and metabolites accounts for approximately 70-80%, with the remainder excreted in feces via biliary elimination.
Renal: >99% as metabolites (hydroxycarisoprodol and meprobamate) and minor unchanged drug. Fecal: <1%. Biliary: negligible.
Approximately 90% bound to plasma proteins, primarily albumin.
Carisoprodol: approximately 60% bound to plasma proteins (predominantly albumin). Meprobamate: ~20% bound.
Volume of distribution is approximately 0.6-1.0 L/kg, indicating distribution into total body water.
Apparent Vd: approximately 0.8 L/kg for carisoprodol (total body water distribution). Clinical meaning: Extensive distribution into tissues; consistent with moderate lipophilicity.
Oral bioavailability is approximately 80-90% due to extensive absorption with minimal first-pass metabolism.
Oral: Approximately 95% absorbed from the GI tract; extensive first-pass metabolism converts ~50% to meprobamate; net bioavailability of parent drug is ~50-60%.
GFR 10-50 m L/min: administer 50-75% of normal dose; GFR <10 m L/min: administer 25-50% of normal dose; hemodialysis: administer after dialysis.
No specific guidelines; use with caution in severe renal impairment (Cr Cl <30 m L/min) due to increased risk of accumulation.
Child-Pugh Class A: no adjustment; Class B: reduce dose by 25-50%; Class C: contraindicated or use with extreme caution, reduce dose by 75%.
Child-Pugh A: no dose adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use.
Children: 10-20 mg/kg/day orally in 2 divided doses; maximum 750 mg/day for <10 kg, 1.5 g/day for 10-20 kg, 2.25 g/day for 20-40 kg, 3 g/day for >40 kg.
Not recommended for use in children under 16 years due to lack of safety and efficacy data.
Elderly: initiate at lower end of dosing range; monitor renal function and adjust dose accordingly; avoid in patients with significant hepatic impairment.
Initiate at 250 mg 3-4 times daily; monitor for sedation and falls; consider reducing dose in frail elderly.
None.
None
Caution in patients with epilepsy or impaired renal function; may cause neurotoxicity at high doses.
Risk of sedation and dizziness, impairing ability to drive or operate machinery,Potential for abuse and dependence, especially with long-term use; meprobamate is a controlled substance,Withdrawal symptoms including anxiety, insomnia, and seizures upon abrupt discontinuation,Hepatic impairment may alter metabolism; use with caution,May cause serotonin syndrome when used with other serotonergic drugs,Respiratory depression with concurrent use of CNS depressants
Hypersensitivity to piperazine; patients with pre-existing neurological disorders such as epilepsy.
Hypersensitivity to carisoprodol or meprobamate,Acute intermittent porphyria,Concomitant use with MAOIs (potential for hypertensive crisis)
No significant food interactions reported. Avoid alcohol as it may increase CNS side effects. Take with food if gastrointestinal upset occurs.
Avoid alcohol. No specific food interactions known, but CNS depressant effects may be exacerbated by alcohol or other sedating substances.
ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. First trimester exposure may be associated with a slightly increased risk of congenital anomalies, though data are limited. Second and third trimester risks are not well-defined; use only if clearly needed.
Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: Limited data suggest a possible increased risk of congenital anomalies, particularly with first-trimester exposure. Second and third trimesters: Use may be associated with neonatal withdrawal syndrome including irritability, tremors, and poor feeding. Avoid use during pregnancy, especially during the first trimester.
Piperazine is excreted into breast milk in small amounts. The M/P ratio is not established. The American Academy of Pediatrics considers piperazine compatible with breastfeeding, but caution is advised due to potential adverse effects in nursing infants. Use only if benefits outweigh risks.
Carisoprodol and its active metabolite meprobamate are excreted into human breast milk. The milk-to-plasma ratio (M/P) is not well established but considered low. However, potential adverse effects in nursing infants include sedation and withdrawal symptoms. The manufacturer recommends caution; avoid breastfeeding while using carisoprodol due to risk of neonatal sedation.
No specific dose adjustments recommended during pregnancy. Piperazine pharmacokinetics may be altered due to increased plasma volume and renal clearance, but standard dosing is generally used. Monitor for efficacy and adverse effects.
Pharmacokinetic changes during pregnancy (increased volume of distribution, altered hepatic metabolism) may reduce carisoprodol concentrations. However, no specific dose adjustments are recommended due to lack of data and potential fetal risks. Use is not recommended in pregnancy; therefore, dose adjustments are not applicable.
ANTEPAR (piperazine) is a first-line treatment for ascariasis and enterobiasis. It causes neuromuscular paralysis in worms via GABA receptor agonism. Contraindicated in epilepsy and renal impairment. Monitor for neurotoxicity (ataxia, confusion) especially in children. Effective against both adult and immature worms; no need for laxatives.
Carisoprodol is centrally acting muscle relaxant that is metabolized to meprobamate, a controlled substance with abuse potential. Avoid in patients with history of substance abuse. Use short-term (2-3 weeks) due to lack of evidence for long-term efficacy. Monitor for sedation and dizziness; avoid concomitant use with other CNS depressants. Taper to discontinue after prolonged use to prevent withdrawal symptoms.
Take exactly as prescribed; complete full course even if symptoms improve.,May cause dizziness or blurred vision; avoid driving until you know how the drug affects you.,Report any muscle weakness, tremors, or confusion to your doctor immediately.,For pinworm infection, all household members should be treated to prevent reinfection.,Practice strict hand hygiene and wash bed linens in hot water to reduce spread.
Take only as prescribed for short-term relief (usually 2-3 weeks).,Do not increase dose or stop abruptly without consulting doctor.,May cause drowsiness, dizziness, or blurred vision; avoid driving or operating machinery until you know how you react.,Avoid alcohol and other sedatives while taking this medication.,Report any signs of abuse or dependence (e.g., craving, needing higher doses).,Do not share this medication with others due to abuse potential.,Seek medical attention if you experience allergic reactions (rash, itching, swelling) or seizures.
No interactions on record
"The co-administration of pentobarbital, a barbiturate and potent CYP3A4 inducer, with carisoprodol, a prodrug that is metabolized to its active form, meprobamate, via CYP2C19, may lead to reduced plasma concentrations of meprobamate due to pentobarbital-induced upregulation of CYP2C19, potentially diminishing the sedative and muscle relaxant effects of carisoprodol. However, pentobarbital also acts as a central nervous system (CNS) depressant, and additive CNS depression can occur, increasing the risk of excessive sedation, respiratory depression, and impairment of psychomotor function. Clinical outcomes may include altered therapeutic efficacy of carisoprodol and heightened risk of CNS and respiratory adverse effects."
"Carisoprodol, a centrally acting skeletal muscle relaxant, is metabolized primarily by CYP2C19 to its active metabolite meprobamate. Isoniazid, a first-line antitubercular agent, is a known inhibitor of CYP2C19. When coadministered, isoniazid can decrease the metabolism of carisoprodol, leading to increased plasma concentrations of both carisoprodol and meprobamate. This elevation raises the risk of dose-related adverse effects such as sedation, dizziness, and respiratory depression, and may prolong the duration of muscle relaxant action."
"The combination of sulpiride, an atypical antipsychotic with dopamine D2 receptor antagonism and mild serotonin 5-HT4 agonist properties, and carisoprodol, a centrally acting muscle relaxant metabolized to meprobamate (a barbiturate-like sedative-hypnotic), can result in additive central nervous system (CNS) depression, including sedation, dizziness, and psychomotor impairment. Additionally, both drugs may lower the seizure threshold, increasing the risk of seizures. Sulpiride can also prolong the QT interval, and carisoprodol's sedative effects may mask or exacerbate this cardiotoxicity, potentially leading to ventricular arrhythmias such as torsade de pointes."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ANTEPAR vs CARISOPRODOL, answered by our medical review team.
ANTEPAR is a Anthelmintic that works by Piperazine, the active ingredient, causes paralysis of the parasite by blocking acetylcholine at the neuromuscular junction and altering muscle membrane ion permeability.. CARISOPRODOL is a Skeletal Muscle Relaxant that works by Carisoprodol is a centrally acting skeletal muscle relaxant that exerts its effects via modulation of GABA-A receptors, possibly through its active metabolite meprobamate, which is a controlled substance with barbiturate-like activity. It also inhibits interneuronal activity in the descending reticular formation and spinal cord, leading to muscle relaxation.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ANTEPAR and CARISOPRODOL depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ANTEPAR is: Adult: 50-75 mg/kg/day orally in 3 divided doses for 3 days; maximum 3 g/day.. The standard adult dose of CARISOPRODOL is: 250-350 mg orally 3 times daily and at bedtime. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ANTEPAR and CARISOPRODOL in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ANTEPAR is classified as Category C. ANTEPAR (piperazine citrate) is classified as FDA Pregnancy Category C. Animal studies have shown embryotoxic effects at high doses, but no well-controlled human studies exist. Fir. CARISOPRODOL is classified as Category A/B. Carisoprodol is classified as FDA Pregnancy Category C. Data from animal studies have shown fetal harm, but no adequate well-controlled studies in pregnant women. First trimester: . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.